Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
The potential benefits of 1.5% hetastarch as a cardioplegia additive
James A. Coles
, Daniel C. Sigg
,
Paul A. Iaizzo
Surgery
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The potential benefits of 1.5% hetastarch as a cardioplegia additive'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Potential Gains
100%
Cardioplegia
100%
Hetastarch
100%
Reperfusion
22%
Myocardial Edema
22%
Clinically Significant
11%
Water Content
11%
Cardiac Function
11%
Swine Heart
11%
Crystalloid
11%
St. Thomas
11%
Creatine Phosphokinase
11%
Diastolic Function
11%
Efflux
11%
Edema
11%
Global Ischemia
11%
Four-chamber
11%
Working Mode
11%
Mitochondrial Creatine Kinase
11%
Left Ventricular End-diastolic Pressure (LVEDP)
11%
Medicine and Dentistry
Cardioplegia
100%
Hydroxyethyl Starch
100%
Edema
33%
Heart Function
11%
Heart Muscle Ischemia
11%
Diastolic Function
11%
Effusion
11%
Heart Left Ventricle Enddiastolic Pressure
11%
Creatine Kinase
11%
Creatine Kinase MB
11%
Veterinary Science and Veterinary Medicine
Cardioplegia
100%
Hydroxyethyl Starch
100%
Ischemia
11%
Effusion
11%
Pharmacology, Toxicology and Pharmaceutical Science
Hetastarch
100%
Edema
33%
Heart Muscle Ischemia
11%
Effusion
11%
Creatine Kinase MB
11%
Creatine Kinase
11%